4.6 Editorial Material

Targeting STING pathways for the treatment of cancer

Journal

ONCOIMMUNOLOGY
Volume 4, Issue 12, Pages -

Publisher

TAYLOR & FRANCIS INC
DOI: 10.4161/2162402X.2014.988463

Keywords

c-di-GMP; IL-12; Listeria-Mage-b; metastatic breast cancer; STING ligand

Funding

  1. NIA NIH HHS [R01 AG023096, T32 AG023475] Funding Source: Medline

Ask authors/readers for more resources

Recently, we demonstrated that stimulator of interferon genes (STING) ligand cyclic di-guanylate (c-di-GMP) is an excellent adjuvant in cancer vaccination but also induces immunogenic tumor cell death. Combination of both pathways resulted in a nearly complete elimination of the metastases in a breast cancer model. This study is discussed below.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available